Cardiovascular
Cardiovascular outcomes, heart failure, cardio-renal protection, hypertension, and lipid-lowering trials in diabetes and endocrinology.
Cotadutide and Albuminuria in Diabetic Kidney Disease: A Phase 2b Trial
A phase 2b randomized trial found that cotadutide reduced urinary albumin-to-creatinine ratio versus placebo in type 2 diabetes with chronic kidney disease, a surrogate signal requiring confirmation. PICO summary and expert commentary.
FLOW Trial: Semaglutide Kidney Benefit With and Without Background SGLT2 Inhibitors
A pre-specified FLOW subgroup analysis tests whether baseline SGLT2 inhibitor use modifies semaglutide's kidney and cardiovascular benefit in type 2 diabetes with CKD. PICO summary and expert commentary.
STEP-HFpEF Pooled Analysis
Pooled subgroup analysis of STEP-HFpEF and STEP-HFpEF-DM finds once-weekly semaglutide 2.4 mg improves symptoms and weight across diuretic strata and cuts loop diuretic dose in obesity-related HFpEF. PICO summary and expert commentary.
Semaglutide and Heart Failure Events in HFpEF: A Post-Hoc Pooled Analysis
A post-hoc pooled analysis of four randomised trials found once-weekly semaglutide lowered the composite of cardiovascular death or worsening heart failure events in patients with HFpEF, with no significant effect on cardiovascular death alone. PICO summary and expert commentary.
FLOW Trial: Semaglutide and Heart Failure Outcomes in Type 2 Diabetes With CKD
A prespecified FLOW analysis found once-weekly semaglutide 1 mg lowered the risk of heart failure events or cardiovascular death in adults with type 2 diabetes and chronic kidney disease. PICO summary and expert commentary.
Semaglutide and Mortality in the SELECT Trial
Secondary analysis of the SELECT trial finds semaglutide 2.4 mg lowered all-cause death in adults with obesity and cardiovascular disease but no diabetes, with much of the non-cardiovascular benefit driven by fewer infectious and COVID-19-related deaths. PICO summary and expert commentary.
STEP-HFpEF: Semaglutide Benefits Consistent Across Baseline Inflammation
A prespecified pooled secondary analysis of the STEP-HFpEF trials found semaglutide improved symptoms, weight, and exercise capacity consistently across baseline C-reactive protein strata and lowered CRP regardless of weight loss. PICO summary and expert commentary.
STEP-HFpEF: Semaglutide and Atrial Fibrillation in Obesity-Related HFpEF
A secondary analysis of the pooled STEP-HFpEF trials found semaglutide improved heart-failure symptoms more in obesity-related HFpEF patients with a history of atrial fibrillation than in those without. PICO summary and expert commentary.